IQ-AI files patent for non-toxic MRI scan technology
IQ-AI Limited (LON:IQAI) – IQ-AI reckons it can eliminate the need for gadolinium-based contrast agents in MRI scans, saving healthcare systems money and avoiding the emerging toxicity concerns
IQ-AI receives first commercial order for StoneChecker
IQ-AI Limited (LON:IQAI) – South Korea is a key market for IQ-AI, with recent research estimating that there are about 300,000 new cases of kidney stone disease each year, despite having a relatively small population of 51mln
IQ-AI’s Imaging Biometrics appoints South Korean distributor as it receives regulatory certification
IQ-AI Limited (LON:IQAI) – The investment firm said that IB’s distributor would sell its full range of imaging products relating to brain tumour detection in the country
IQ-AI’s portfolio gains commercial and regulatory traction following name change
IQ-AI Limited (LON:IQAI) – The firm’s subsidiary, Imaging Biometrics, recently appointed a South Korean distributor a few weeks after receiving the first commercial order for its StoneChecker technology
IQ-AI focused on developing global markets for its Imaging Biometrics’ products
David Smith, chief executive of IQ-AI Limited’s (LON:IQAI) operating subsidiaries, spoke to Proactive London’s Andrew Scott soon after Imaging Biometrics appointed a South Korean distributor for its diagnostic imaging products.
IQ-AI’s Imaging Biometrics has software platform installed at Barrow Neurological Institute
IQ-AI Limited (LON:IQAI) – The investment firm said IB’s Rad Tech software would be used to help assess treatment response options for patients with brain tumours
IQ-AI expecting the FDA to complete its review of Stonechecker by end of first quarter 2019
IQ-AI Limited (LON:IQAI) – StoneChecker was originally submitted to FDA in May 2018. It is not uncommon for the process to have a certain amount of ‘to-and-fro’ between the FDA and the company making the submission
IQ-AI surges after raising £268,500 in loan notes issue
IQ-AI Limited (LON:IQAI) – Trevor Brown, the company’s chief executive, subscribed for £250,000 of the loan notes while Imaging Biometrics, IQ-AI’s subsidiary, subscribed for the other £18,500
Flying Brands appoints experienced executive to run its two subsidiaries
IQ-AI Limited (LON:IQAI) – David Smith brings with him a track record of business development
Flying Brands on track for commercial roll-out of StoneChecker software later this year
IQ-AI Limited (LON:IQAI) – The medical imaging specialist said it is “excited” for the rest of the year, with approval from US regulators for its StoneChecker software expected soon
Flying Brands’ David Smith on product pipeline and Stonechecker FDA application
David Smith, chief operating officer of Flying Brands Limited (LON:FBDU) and chief executive of operating companies StoneChecker and Imaging Biometrics caught up with Proactive’s Andrew Scott while in London.
Flying Brands jumps as Imaging Biometrics inks agreement to develop diagnostic tool for liver cirrhosis
IQ-AI Limited (LON:IQAI) – The firm said Imaging would work with the University of Alabama to develop a product to quantify liver surface nodularity, which allows prediction of cirrhosis
IQ-AI files patent for non-toxic MRI scan technology
IQ-AI Limited (LON:IQAI) – IQ-AI reckons it can eliminate the need for gadolinium-based contrast agents in MRI scans, saving healthcare systems money and avoiding the emerging toxicity concerns
IQ-AI’s David Smith updates on patents and StoneChecker FDA process
David Smith, chief executive of IQ-AI Limited’s (LON:IQAI) operating subsidiaries, spoke to Proactive London’s Andrew Scott about the recent filing of a patent for gadolinium-free magnetic resonance imaging (MRI) scan.